As cell and gene therapy scales, DNA choice matters. Learn the advantages of cell‑free DNA vs pDNA in this Q&A with Touchlight’s CSO.
Read More
Touchlight is proud to announce a strategic partnership with SVF Vaccines to progress SVF’s innovative Hepatitis B/D vaccine into clinical development.
Read More
This application note presents a comparative study of enzymatically manufactured doggybone DNA™ (dbDNA™) versus traditional plasmid DNA (pDNA) for lentiviral vector (LVV) production, using the FuGENE® 4K transfection reagent. The…
Read More
Discover how Touchlight’s novel circular DNA architectures—mbDNA™, sscDNA, hsscDNA, and dscDNA—enable precise, efficient gene insertion for next‑generation gene editing and non‑viral gene therapy.
Read More
Touchlight and New England Biolabs launch the EnClose™ Cell‑free dbDNA™ Synthesis Kit, enabling rapid, scalable, cell‑free production of high‑purity DNA for next‑generation mRNA, gene therapy, and vector development.
Read More
This application note presents an independent cost-of-goods (COG) analysis conducted by Decisional Point Limited to evaluate the financial impact of switching from plasmid DNA (pDNA) to Touchlight’s enzymatically produced dbDNA™…
Read More
Plasmid DNA has long been the workhorse of cell and gene therapy — supporting countless clinical programs and enabling many of the field’s most important breakthroughs. At the same time,…
Read More
